Sakshi Singh
Enzyme inhibitors have emerged as powerful therapeutic agents in drug discovery and development. Targeting specific enzymes involved in disease-related pathways provides opportunities for modulating biological processes and treating various disorders. This review explores different strategies and challenges in the design of enzyme inhibitors for therapeutic purposes. The study begins by highlighting the importance of enzyme inhibition as a strategy for modulating enzyme activity and interfering with disease processes. Enzyme inhibitors can exert their effects by blocking the active site of the enzyme, disrupting cofactor binding, or interfering with protein-protein interactions crucial for enzyme function. These inhibitors can be classified into different categories based on their mechanism of action, including reversible and irreversible inhibitors, competitive and non-competitive inhibitors, and allosteric modulators. The review then discusses various strategies employed in the design and development of enzyme inhibitors. Structure-based drug design, utilizing the three-dimensional structure of the enzyme and computer-aided drug design techniques, enables the rational design of inhibitors with improved potency and selectivity. High-throughput screening of compound libraries allows for the identification of lead compounds that can be further optimized through medicinal chemistry approaches. Fragment-based drug design, virtual screening, and natural product-based drug discovery are additional strategies utilized in the design of enzyme inhibitors. However, the design of enzyme inhibitors also presents several challenges. Achieving selectivity and specificity is crucial to avoid off-target effects and minimize potential toxicity. Overcoming drug resistance, often arising from mutations in the target enzyme, requires the development of innovative strategies such as combination therapies or the targeting of alternative pathways. Pharmacokinetic considerations, including bioavailability, metabolic stability, and drug-drug interactions, also need to be addressed during the design and optimization of enzyme inhibitors. Moreover, the review discusses emerging trends and technologies in the field of enzyme inhibitor design. These include the utilization of covalent inhibitors, which form irreversible bonds with the target enzyme, and the development of allosteric inhibitors that modulate enzyme activity by binding to remote sites. The use of nanotechnology and drug delivery systems offers opportunities for targeted delivery and improved therapeutic efficacy of enzyme inhibitors. In conclusion, enzyme inhibitors represent promising therapeutic agents in drug design. The strategies employed in their design, including structure-based drug design, high-throughput screening, and fragment-based drug discovery, have led to significant advancements. However, challenges such as achieving selectivity, overcoming drug resistance, and optimizing pharmacokinetic properties remain. Continued research and technological advancements in the field hold promise for the development of novel enzyme inhibitors with improved efficacy and safety profiles, ultimately leading to the discovery of new treatments for various diseases.
KeywordsBinding affinity; Structure-based drug design; Ligand-based drug design
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu